Skip to main content
Delfa

← All assets

Subcutaneous · Amylin analog

NNC0638-0355

1 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.

Trials

1

Ongoing

1

Recruiting

0

Completed

0

Sites

1

Countries

1

Endpoints

6

Composite endpoints

0

Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.

Where the program stands

Trials by phase

Phase 1
1

Trials by status

Active, not recruiting
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Safety / tolerability / PK
6

Top 20 metrics across this asset's endpoints

Programs for this asset

Every trial for this molecule, with the same search, filters, and sort as the Trials tab.

1 of 1

GLP-1 and incretin trials
Asset / PopulationEligibility highlightEvidence
NCT06577766A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity

NNC0638-0355

Obesity / overweight

BMI 25-34.9Ph 1Active, not recruiting1Sep 2026-

Showing 1-1 of 1 trials